ESR1-Driven Resistance to CDK4/6 Inhibitors in Breast Cancer Thwarted by SERDs

(MedPage Today) -- Mutations in ESR1 do not appear to confer breast cancer resistance to cyclin-dependent kinase (CDK)4/6 inhibitors, an analysis of clinical practice data suggested.
Patients with metastatic hormone receptor-positive breast cancer...